NKTR-255
Phase 2Small molecule
NKTR-255 is one of 48 small molecule programs targeting Lung Cancer. It is currently in Phase 2.
3
Indications
5
Total Trials
3
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
206 competitors in Lung Cancer
#DrugCompanyPhaseTrials
1Beyfortus
BeiGenePhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Alecensa
RochePhase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Tarlatamab-Dznl
AmgenPhase 3
DATROWAY
Daiichi SankyoPhase 3
Ilaris
NovartisPhase 3
Verzenio
Eli LillyPhase 3
Lynparza
AstraZenecaPhase 3
Hycamtin
MMeitheal
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Recurrent or Refractory1 trial
Locally Advanced or Metastatic Urothelial Carcinoma1 trial
A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)
Active, not recruiting·
EMD Serono Research & Development Institute, Inc.·Phase 2·NCT05327530·256 enrolled
EMD Serono Research & Development Institute, Inc.·Phase 2·NCT05327530·256 enrolledSources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NKTR-255. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNektar Therapeutics